Case Western Reserve researchers use AI with routine CT scans to predict how well lung cancer patients will respond to expensive treatment based off changes in texture patterns inside and outside the tumor.
Scientists from the Case Western Reserve University digital imaging lab, already pioneering the use of Artificial Intelligence (AI) to predict whether chemotherapy will be successful, can now determine which lung-cancer patients will benefit from expensive immunotherapy.
And, once again, they’re doing it by teaching a computer to find previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy treatment. And, as with previous work, those changes have been discovered both inside—and outside—the tumor, a signature of the lab’s recent research.
“This is no flash in the pan—this research really seems to be reflecting something about the very biology of the disease, about which is the more aggressive phenotype, and that’s information oncologists do not currently have,” said Anant Madabhushi, whose Center for Computational Imaging and Personalized Diagnostics (CCIPD) has become a global leader in the detection, diagnosis and characterization of various cancers and other diseases by meshing medical imaging, machine learning and AI.
Currently, only about 20% of all cancer patients will actually benefit from immunotherapy, a treatment that differs from chemotherapy in that it uses drugs to help your immune system fight cancer, while chemotherapy uses drugs to directly kill cancer cells, according to the National Cancer Institute.
Madabhushi said the recent work by his lab would help oncologists know which patients would actually benefit from the therapy, and who would not.
“Even though immunotherapy has changed the entire ecosystem of cancer, it also remains extremely expensive—about $200,000 per patient, per year,” Madabhushi said. “That’s part of the financial toxicity that comes along with cancer and results in about 42% of all new diagnosed cancer patients losing their life savings within a year of diagnosis.”
Having a tool based on the research being done now by his lab would go a long way toward “doing a better job of matching up which patients will respond to immunotherapy instead of throwing $800,000 down the drain,” he added, referencing the four patients out of five who will not benefit, multiplied by annual estimated cost.
New research published
The new research, led by co-authors Mohammadhadi Khorrami and Prateek Prasanna, along with Madabhushi and 10 other collaborators from six different institutions (see list, below) was published this month in the journal Cancer Immunology Research.
Khorrami, a graduate student working at the CCIPD, said one of the more significant advances in the research was the ability of the computer program to note the changes in texture, volume and shape of a given lesion, not just its size.
“This is important because when a doctor decides based on CT images alone whether a patient has responded to therapy, it is often based on the size of the lesion,” Khorrami said. “We have found that textural change is a better predictor of whether the therapy is working.
“Sometimes, for example, the nodule may appear larger after therapy because of another reason, say a broken vessel inside the tumor—but the therapy is actually working. Now, we have a way of knowing that.”
Prasanna, a postdoctoral research associate in Madabhushi’s lab, said the study also showed that the results were consistent across scans of patients treated at two different sites and with three different types of immunotherapy agents.
“This is a demonstration of the fundamental value of the program, that our machine-learning model could predict response in patients treated with different immune checkpoint inhibitors,” he said. “We are dealing with a fundamental biological principal.”
Prasanna said the initial study used CT scans from 50 patients to train the computer and create a mathematical algorithm to identify the changes in the lesion. He said the next step will be to test the program on cases obtained from other sites and across different immunotherapy agents. This research recently won an ASCO 2019 Conquer Cancer Foundation Merit Award.
Additionally, Madabhushi said, researchers were able show that the patterns on the CT scans which were most associated with a positive response to treatment and with overall patient survival were also later found to be closely associated with the arrangement of immune cells on the original diagnostic biopsies of those patients.
This suggests that those CT scans actually appear to capturing the immune response elicited by the tumors against the invasion of the cancer—and that the ones with the strongest immune response were showing the most significant textural change and most importantly, would best respond to the immunotherapy, he said.
Madabhushi established the CCIPD at Case Western Reserve in 2012. The lab now includes nearly 60 researchers.
Some of the lab’s most recent work, in collaboration with New York University and Yale University, has used AI to predict which lung cancer patients would benefit from adjuvant chemotherapy based on tissue-slide images. That advancement was named by Prevention Magazine as one of the top 10 medical breakthroughs of 2018.
Learn more: Using Artificial Intelligence to determine whether immunotherapy is working
The Latest Google Headlines on:
Immunotherapy
[google_news title=”” keyword=”immunotherapy ” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Immunotherapy
- Supercharging immune cells to battle blood cancer: breakthrough in cancer immunotherapyon May 8, 2024 at 10:42 pm
A new study reveals a groundbreaking approach to immunotherapy, demonstrating that blocking the interaction between the CD300A receptor and ...
- How new immunotherapy is helping treat advanced stage 4 melanomaon May 8, 2024 at 12:48 pm
Oncologists say the single-dose immunotherapy is currently approved for those with advanced stage 4 melanoma, who have not had success with other treatments. The process works by surgically removing a ...
- Biotech CEL-SCI gets FDA go-ahead to conduct investigational cancer immunotherapy studyon May 8, 2024 at 11:18 am
Listen to this article CEL-SCI Corporation, the Vienna, Virginia-based biotechnology company with operations in Baltimore, Wednesday received approval from the U.S. Food and Drug Administration to ...
- Can Vitamin D Improve Cancer Immunotherapy?on May 8, 2024 at 6:30 am
Your diet could impact your cancer treatment’s progress; a new preclinical study suggests more vitamin D could improve responses to checkpoint inhibitors.
- FDA approves new immunotherapy treatment for melanomaon May 6, 2024 at 5:45 pm
Melanoma is considered the deadliest of all skin cancers. Now the FDA has approved an immunotherapy treatment that could help extend lives. The single-dose immunotherapy is currently approved for ...
- Study uncovers at least one cause of roadblocks to cancer immunotherapyon May 6, 2024 at 9:39 am
"These findings uncover new tactics that are employed by cancer to escape from immune cell attack and explain why some cancer immunotherapy strategies do not work well in the clinic," said Lieping ...
- Many Patients With Advanced MCC Not Receiving Immunotherapyon May 5, 2024 at 9:36 pm
Despite improved survival rates and guideline recommendations, many eligible patients with metastatic Merkel cell carcinoma are not receiving immunotherapy.
- Immunotherapy: A Beacon of Hope in Cancer Treatmenton May 4, 2024 at 2:25 pm
Cancer, a disease that has plagued humanity for centuries, has finally met its match in immunotherapy, a revolutionary treatment that harnesses the power of the immune system to combat this deadly ...
- Ketone supplement may boost immunotherapy against prostate canceron May 2, 2024 at 9:00 am
Researchers have found that adding a pre-ketone supplement to immunotherapy boosted its effectiveness against prostate cancer in mouse models.
- Breaking: AI Could Transform Cancer Treatment by Predicting Immunotherapy Successon April 30, 2024 at 8:27 am
In this article, we’ll explore a breakthrough development in the fight against cancer: how artificial intelligence (AI) is poised to predict immunotherapy success. This has the potential to ...
The Latest Google Headlines on:
Artificial intelligence diagnostics
[google_news title=”” keyword=”artificial intelligence diagnostics” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Artificial intelligence diagnostics
- Progressive Role of Artificial Intelligence in Treatment Decision - Making in the Field of Medical Oncologyon May 8, 2024 at 2:49 am
Artificial intelligence (AI) has started to play an important role in oncologic medicine today, focusing mainly on oncologic diagnosis (by helping in cancer radiology & pathology) and radiation ...
- Quest Diagnostics (DGX) Grows in Digital Pathology With New Dealon May 7, 2024 at 8:23 am
Quest Diagnostics DGX recently announced a strategic collaboration with PathAI, a global leader in artificial intelligence-powered pathology technology, aimed at revolutionizing cancer and disease ...
- Quest plans to purchase PathAI’s diagnostic lab as part of AI ramp-upon May 6, 2024 at 9:18 am
AI and digital technologies have tremendous potential to improve cancer care, and Quest has the know-how to scale and deliver innovations that are high quality, efficient and broadly accessible," said ...
- Artificial Intelligence in Diagnostics Market CAGR of 32.3%, Size Poised for Takeoff in the Coming Yearson May 5, 2024 at 2:43 pm
Artificial Intelligence in Diagnostics Market is valued approximately at USD 288 million in 2019 and is anticipated to grow with a healthy growth rate of more than 32.3% over the forecast period ...
- Artificial intelligence expands diagnostic horizons in coronary angiographyon May 3, 2024 at 6:46 am
New insights from the AI-ENCODE study showed artificial intelligence (AI) successfully allowed the ... Coronary angiography is a widely used diagnostic procedure for identifying coronary artery ...
- Quest Finds its Path to AI in Cancer Diagnostics Through M&Aon May 1, 2024 at 10:25 am
Quest Diagnostics has found its path to artificial intelligence in cancer diagnosis through M&A. The Secaucus NJ-based company said it was acquiring select assets of PathAI Diagnostics, the business ...
- 16 Surprising Ways AI Enhances Healthcare Diagnostics And Deliveryon May 1, 2024 at 10:14 am
Many patients might be surprised to learn just how big an impact AI is poised to make in modern healthcare delivery.
- Quest Diagnostics carves out PathAI's digital pathology lab, plots AI ramp-upon May 1, 2024 at 7:30 am
Quest Diagnostics is building out its artificial intelligence-powered cancer pathology offerings through a multi-layered deal with PathAI—acquiring some assets, licensing out others. | Quest ...
- Quest Diagnostics To Acquire Select Assets Of PathAI Diagnostics - Quick Factson May 1, 2024 at 4:31 am
Quest Diagnostics (DGX) and PathAI, a global provider of artificial intelligence-powered technology for pathology, announced ...
- Artificial Intelligence in Diagnostics Market To Reach USD 7.8 Billion By 2032 | DataHorizzon Researchon April 30, 2024 at 11:40 pm
The artificial intelligence in diagnostics market size valued at USD 0.7 Billion in 2022 and is anticipated to reach USD 7.8 Billion by 2032 at a CAGR of 26.4%.Fort Collins, Colorado, May 01, 2024 ...